Advertisement
Advertisement
Money /

Money News

Related Topics:
Banking & finance
XXXXXXX Photo: Karma Lo
Banking & finance

Will Hong Kong’s board-lot reform bump HSBC’s share turnover?

The minimum investment of nearly US$8,000 for one of Hongkongers’ favourite stocks is set to drop. The question is how low it will go.

Wealth management

Most ultra-rich expats plan to retire in Hong Kong, fuelled by financial perks

36
Gold in Hong Kong

China gold ETFs see record US$2.91 billion outflow in June as risk appetite returns

Banking & finance

Southbound Stock Connect flows surge to record US$152b amid Hong Kong IPO boom

Average daily southbound turnover soared 84 per cent year on year to HK$124.1 billion, equal to 24 per cent of city’s total market turnover.

An exterior view of the Hong Kong stock exchange in Central on March 13, 2026. Photo: Jelly Tse
An exterior view of the Hong Kong stock exchange in Central on March 13, 2026. Photo: Jelly Tse
Millionaires, billionaires and trillionaires

What’s powering the rapid rise of Hong Kong’s ultra-wealthy class?

The city’s ultra-wealthy population jumped by more than 26 per cent in 2025 – roughly one super-rich individual for every 412 residents.

videocam
ETFs

Is FOMO driving South Korean investors to Hong Kong to cash in on AI and chips?

Some South Korean retail investors are turning to Hong Kong’s leveraged semiconductor ETFs for higher AI-driven returns.

Advertisement
Advertisement
Advertisement
IPO

As Musk becomes first trillionaire from SpaceX IPO, will next come from China?

As the initial public offering sees Musk become the first ever trillionaire, China is also seeing growth in its tech uber-rich.

17
Elon Musk in Beijing on May 14. Photo: AP
Elon Musk in Beijing on May 14. Photo: AP
China stock market

Emerging markets rebound on inflows as Xi-Trump talks eyed for momentum

Mainland China, Hong Kong stock markets may benefit from Xi-Trump meeting as renewed interest in AI shows investors keen to re-engage, analysts say.

videocam
Banking & finance

Hong Kong secures US$3.5 billion to fund Northern Metropolis and green projects

Global investors pile into city’s latest bond sale, with orders 7.6 times oversubscribed, backing its green finance ambitions.

China’s private sector

China’s drug makers are speeding up – will AI be their secret weapon?

Chinese biotech firms are striking big global deals as drug makers, but could artificial intelligence take them to the next level?

Illustration by Henry Wong
Banking & finance

Global funds fuel Hong Kong IPO rebound as investors rebalance China portfolios

AI, robotics and energy storage firms make up most of the record-high IPO pipeline in Hong Kong, says Chan.

HKEX CEO Bonnie Chan Yiting speaks at the Chinese New Year Market Open Celebration at HKEX in Central, on February 20. Photo: Karma Lo
HKEX CEO Bonnie Chan Yiting speaks at the Chinese New Year Market Open Celebration at HKEX in Central, on February 20. Photo: Karma Lo
Banking & finance

China healthcare stocks shine in Hong Kong amid Middle East turmoil

Hang Seng Healthcare Index outpaces broader market as Akeso, Innovent, Hansoh provide refuge for global investors.

Banking & finance

OKX Ventures, HashKey Capital back Vietnam crypto platform’s pilot scheme bid

Under pilot rules, at least 65 per cent of capital must come from institutional investors and foreign ownership is capped at 49 per cent.

Banking & finance

Mainland China and Hong Kong IPOs drive Citic to the top of banking fee rankings

Citic leads Asia-Pacific in fees in the first quarter as IPOs in Hong Kong and mainland China offset weaker debt and M&A activity.

Citic Securities led Asia-Pacific with a 6.4 per cent share of the total investment banking fee pool in the first quarter: Photo. Reuters
Banking & finance

Stricter Chinese scrutiny of offshore vehicles a blow for tech IPO candidates

Mainland’s stock market watchdog is discouraging establishment of ‘red-chip-structured’ companies in sensitive industries.

Many Chinese biotech and tech firms favour red-chip structures. Photo: Shutterstock
Many Chinese biotech and tech firms favour red-chip structures. Photo: Shutterstock
China’s private sector

Rights to antibody drug from China’s Keymed change hands in US acquisition

Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.

Banking & finance

Iran conflict drives fund managers to slash risk and hoard cash: BofA survey

Fund managers pile into cash at fastest pace since Covid-19 as geopolitical tensions, inflation replace AI as top concerns, bank finds.

Advertisement
Advertisement
Advertisement
Banking & finance

Chinese banks outpace rivals in Hong Kong wealth growth, Huatai HK CEO says

Booming listings and rising outbound investment demand are accelerating growth for Chinese players, SFC data shows.

Wang Lei, CEO of Huatai Financial. Photo: Handout
Wang Lei, CEO of Huatai Financial. Photo: Handout
China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Banking & finance

Hong Kong attracts wave of biotech IPO filings amid AI drug research boom

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest.

Biomedicine: Companies

In a first for China, Neuracle’s brain-computer interface wins approval

China’s BCI start-ups, seen as potential rivals to Elon Musk’s Neuralink, gain momentum as regulatory support and new capital fuel growth.

A man demonstrates a robotic hand with a brain-computer interface at the China International Import Expo on November 7, 2025. Neuracle’s regulatory milestone underscores China’s accelerating push in neurotechnology. Photo: AFP
Banking & finance

Hong Kong family offices take long view despite Iran war, HKMA affiliate says

Survey shows family offices expanding risk management while maintaining strong investment exposure to Hong Kong and Asia.

Family offices are increasingly using hedging strategies and derivative instruments to manage portfolio risks, according to a survey. Photo: Sam Tsang
Family offices are increasingly using hedging strategies and derivative instruments to manage portfolio risks, according to a survey. Photo: Sam Tsang
Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Stock Connect reshuffle reflects biotech sector’s growing role on international stage, though overseas funds remain cautious.

Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua
Help preserve 120 years of quality journalism.
SUPPORT NOW